News – Page 121 – Endpoints News

Taking advantage of recent successes, Roche will push obesity drugs faster, flirts with M&A

9 months ago

AbbVie beats expectations with smaller Humira slide — and big gains for next autoimmune blockbusters

9 months ago

AstraZeneca details ‘very ambitious’ strategy for early-stage obesity programs

9 months ago

Sanofi shelves four assets, including mid-stage dwarfism candidate

9 months ago

Galderma deprioritizes study for IL-31 drug; UCB stops work in rare encephalitis

9 months ago

AbbVie expects $8.7B Cerevel buy to close ‘as early as next week,’ new CEO says

9 months ago

Novo Nordisk considers another facility; Lonza’s new CEO shares his priorities

9 months ago

Manatt scoops up health tech experts Christina Farr and Tom Cassels

9 months ago

Sanofi eyes RSV antibody for its next blockbuster while Dupixent brings in record sales

9 months ago

Roche cuts two more TIGIT trials, plans accelerated timeline for obesity drugs

9 months ago

Updated: AstraZeneca says there’s ‘very limited’ impact on Farxiga after US drug pricing negotiations

9 months ago

BioMarin snags expanded Brineura label, now approved for all kids regardless of symptoms

9 months ago

Exclusive: After selling Mirati to BMS for nearly $5B, Chuck Baum lands at another ‘undruggable’ company

9 months ago

Ipsen pays Day One $111M upfront for ex-US rights to pediatric brain tumor drug

9 months ago

Argenx to retest Vyvgart in autoimmune platelet disease after failure last year

9 months ago

Viking to push obesity drug to Phase 3 in bid to reach market faster

9 months ago

Republican-led states can't intervene in case on abortion pill restrictions, appeals court says

9 months ago

US bankrolls a third of global Pandemic Fund. Can it get congressional support?

9 months ago

FDA finalizes guidance on using EHR data to support drug submissions

9 months ago

Rare pediatric PRV reauthorization faces uncertain fate as summer recess approaches

9 months ago

In a tough market, private biotechs pursue IPOs and buyouts at the same time

9 months ago

Novartis pays $150M upfront, including $25M in equity, for Dren Bio’s bispecifics

9 months ago

BioNTech signs 3D printing deal to develop oral RNA drugs

9 months ago

Palvella’s reverse merger with Pieris; AbbVie’s VC arm invests in anti-aging startup

9 months ago

First page Previous page 118 119 120121122 123 124 Next page Last page